Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy plus QL1706 + CAPOX + bevacizumab for first-line treatment of MSS metastatic colorectal cancer
ChiCTR2500111769Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in colorectal adenocarcinoma, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500111769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111769.